Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

• Published in: Viruses Vol. 13; no. 8; p. 1498
• Main Authors: Halwe, Sandro, Kupke, Alexandra, Vanshylla, Kanika, Liberta, Falk, Gruell, Henning, Zehner, Matthias, Rohde, Cornelius, Krähling, Verena, Gellhorn Serra, Michelle, Kreer, Christoph, Klüver, Michael, Sauerhering, Lucie, Schmidt, Jörg, Cai, Zheng, Han, Fei, Young, David, Yang, Guangwei, Widera, Marek, Koch, Manuel, Werner, Anke, Kämper, Lennart, Becker, Nico, Marlow, Michael S., Eickmann, Markus, Ciesek, Sandra, Schiele, Felix, Klein, Florian, Becker, Stephan
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 29-07-2021; MDPI
• Subjects: animal experiments; Antibodies; Antiviral agents; Bioavailability; Clinical trials; Coronaviruses; COVID-19; Disease transmission; Intranasal administration; Laboratories; mice; Microscopy; Monoclonal antibodies; monoclonal antibody; neutralizing antibody; Pandemics; Pharmacokinetics; Proteins; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Software; Spike protein; virus; Canada; United States > US
• ISSN: 1999-4915; 1999-4915
• DOI: 10.3390/v13081498

Despite the recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the global fight against the SARS-CoV-2 pandemic due to their ability to convey immediate protection and their potential to be used as both prophylactic and therapeutic drugs. Clinically used neutralizing antibodies against respiratory viruses are currently injected intravenously, which can lead to suboptimal pulmonary bioavailability and thus to a lower effectiveness. Here we describe DZIF-10c, a fully human monoclonal neutralizing antibody that binds the receptor-binding domain of the SARS-CoV-2 spike protein. DZIF-10c displays an exceptionally high neutralizing potency against SARS-CoV-2, retains full activity against the variant of concern (VOC) B.1.1.7 and still neutralizes the VOC B.1.351, although with reduced potency. Importantly, not only systemic but also intranasal application of DZIF-10c abolished the presence of infectious particles in the lungs of SARS-CoV-2 infected mice and mitigated lung pathology when administered prophylactically. Along with a favorable pharmacokinetic profile, these results highlight DZIF-10c as a novel human SARS-CoV-2 neutralizing antibody with high in vitro and in vivo antiviral potency. The successful intranasal application of DZIF-10c paves the way for clinical trials investigating topical delivery of anti-SARS-CoV-2 antibodies.